De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Advicenne Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Advicenne has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 6.2% per year.
Belangrijke informatie
8.9%
Groei van de winst
14.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 16.3% |
| Inkomstengroei | 6.2% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -264.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Advicenne geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -9 | 4 | 5 |
| 31 Mar 24 | 3 | -8 | 4 | 5 |
| 31 Dec 23 | 3 | -7 | 4 | 4 |
| 30 Sep 23 | 3 | -9 | 4 | 5 |
| 30 Jun 23 | 3 | -10 | 4 | 6 |
| 31 Mar 23 | 3 | -11 | 5 | 7 |
| 31 Dec 22 | 3 | -11 | 5 | 7 |
| 30 Sep 22 | 3 | -10 | 5 | 7 |
| 30 Jun 22 | 4 | -9 | 5 | 7 |
| 31 Mar 22 | 4 | -11 | 6 | 8 |
| 31 Dec 21 | 4 | -12 | 6 | 9 |
| 30 Sep 21 | 4 | -14 | 5 | 6 |
| 30 Jun 21 | 4 | -15 | 8 | 8 |
| 31 Mar 21 | 4 | -15 | 9 | 8 |
| 31 Dec 20 | 3 | -15 | 9 | 8 |
| 30 Sep 20 | 3 | -15 | 11 | 11 |
| 30 Jun 20 | 3 | -15 | 4 | 1 |
| 31 Mar 20 | 2 | -14 | 4 | 0 |
| 31 Dec 19 | 3 | -14 | 8 | 9 |
| 30 Sep 19 | 2 | -11 | 6 | 5 |
| 30 Jun 19 | 2 | -8 | 5 | 1 |
| 31 Mar 19 | 1 | -6 | 4 | 1 |
| 31 Dec 18 | 1 | -5 | 3 | 0 |
| 30 Sep 18 | 2 | -6 | 3 | 3 |
| 30 Jun 18 | 2 | -7 | 4 | 6 |
| 31 Mar 18 | 2 | -7 | 4 | 5 |
| 31 Dec 17 | 3 | -6 | 3 | 5 |
| 30 Sep 17 | 2 | -5 | 3 | 4 |
| 30 Jun 17 | 2 | -4 | 2 | 4 |
| 31 Mar 17 | 2 | -4 | 2 | 4 |
| 31 Dec 16 | 2 | -4 | 2 | 3 |
| 31 Dec 15 | 3 | -2 | 1 | 0 |
| 31 Dec 14 | 2 | -2 | 1 | 0 |
Kwaliteitswinsten: ALDVI is currently unprofitable.
Groeiende winstmarge: ALDVI is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ALDVI is unprofitable, but has reduced losses over the past 5 years at a rate of 8.9% per year.
Versnelling van de groei: Unable to compare ALDVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ALDVI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-19.9%).
Rendement op eigen vermogen
Hoge ROE: ALDVI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.